Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Leases: 2014-2025

Historic Current Leases for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Sep 2025 value amounting to $1.0 million.

  • Lineage Cell Therapeutics' Current Leases fell 5.54% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 5.54%. This contributed to the annual value of $1.1 million for FY2024, which is 32.17% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Current Leases stood at $1.0 million, which was up 2.51% from $998,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Current Leases high stood at $1.1 million for Q1 2025, and its period low was $543,000 during Q3 2022.
  • In the last 3 years, Lineage Cell Therapeutics' Current Leases had a median value of $1.0 million in 2025 and averaged $1.0 million.
  • Over the last 5 years, Lineage Cell Therapeutics' Current Leases had its largest YoY gain of 64.14% in 2021, and its largest YoY loss of 36.61% in 2021.
  • Lineage Cell Therapeutics' Current Leases (Quarterly) stood at $801,000 in 2021, then increased by 14.36% to $916,000 in 2022, then dropped by 9.39% to $830,000 in 2023, then soared by 32.17% to $1.1 million in 2024, then dropped by 5.54% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $998,000 for Q2 2025, and $1.1 million during Q1 2025.